文献速递类风湿关节炎其他结缔组织病

利妥昔单抗治疗下炎症性风湿病患者COVID-19疫苗的体液免疫原性:病例对照研究(COVID-19VacRTX)

Humoral immunogenicity of COVID-19 vaccines in patients with inflammatory rheumatic diseases under treatment with Rituximab: a case-control study (COVID-19VacRTX).
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

该病例对照研究纳入102例既往接受利妥昔单抗(RTX)治疗的炎症性风湿病患者,评估完成首轮COVID-19疫苗接种后的体液免疫应答。65例(64%)接种后抗体水平为阴性(<24 IU/ml),末次RTX输注与首次接种间隔与抗体水平显著相关(P=0.0008),72%患者未检出外周CD19+ B细胞。

要点

  • 64%接受RTX治疗的炎症性风湿病患者接种COVID-19疫苗后抗体阴性(<24 IU/ml)。
  • 末次RTX输注与首次接种间隔与抗体水平显著相关(P=0.0008)。
  • 72%患者未检出外周CD19+ B细胞,抗体滴度与B细胞数量及免疫球蛋白量相关。

核心结论

  • 研究证实RTX对SARS-CoV-2疫苗接种后抗体水平有负面影响。
  • 抗体滴度与末次RTX输注至首次接种的间隔、外周B细胞数量及免疫球蛋白量之间存在明确关系。
  • 更好地理解这些参数的作用有助于指导疫苗接种与RTX治疗方案的同步安排。

研究设计与样本

  • 病例对照研究,纳入既往接受RTX治疗的炎症性风湿病患者,评估完成首轮获批疫苗接种后的体液免疫应答。
  • 使用Euroimmun Anti-SARS-CoV-2 QuantiVac ELISA(EI-S1-IgG-quant)定量抗体水平,血样于接种后下一次RTX输注前采集。
  • 共纳入102例患者。

主要发现

  • 102例中65例(64%)接种后抗体水平为阴性(<24 IU/ml)。
  • 末次RTX输注与首次SARS-CoV-2疫苗接种间隔的单因素分析结果显著(P=0.0008)。
  • 73例患者(72%)未检出外周CD19+ B细胞。

关键数值与推荐

  • 抗体阴性定义为<24 IU/ml,102例中65例(64%)为阴性。
  • 末次RTX输注与首次接种间隔的单因素分析P=0.0008。
  • 73例(72%)未检出外周CD19+ B细胞。

临床怎么用

  • 原文结论指出,更好地理解这些参数的作用有助于指导疫苗接种与RTX治疗方案的同步安排。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Patients with inflammatory rheumatic diseases (IRDs) treated with the anti-CD20 mAb rituximab (RTX) have been identified as high-risk for severe COVID-19 outcomes. Additionally, there is increased risk due to reduced humoral immune response, induced by therapeutic B cell depletion. This study sought to quantify humoral response after vaccination against SARS-CoV-2 in patients with IRD treated with RTX. It also sought to elucidate the influence of the time frame between the last RTX dose and the first vaccination, or the status of B cell depletion on antibody titre. METHODS: In this case-control study, patients with IRDs previously treated with RTX were examined for humoral immune response after completing the first series of vaccinations with approved vaccines [BNT162b2 (Biontech/Pfizer), RNA-1273 (Moderna), AZD1222 (AstraZeneca/Oxford), Ad26.COV2.S (Janssen/Johnson & Johnson)]. Antibody levels were quantified using the Euroimmun Anti-SARS-CoV-2 QuantiVac ELISA (EI-S1-IgG-quant). Blood samples were taken just before the next infusion with RTX after the vaccination. The interval between the last RTX infusion and the first vaccination against SARS-CoV-2 and other possible factors influencing the antibody levels were evaluated. RESULTS: A total of 102 patients were included. Of these, 65 (64%) showed a negative antibody level (<24 IU (international unit)/ml) after the vaccination. The comparative univariate analysis of the antibody levels achieved a significant result (P = 0.0008) for the time between the last RTX infusion and first vaccination against SARS-CoV-2. No CD19+ peripheral B-cells could be detected in 73 of the patients (72%). CONCLUSION: The study confirms the negative impact of RTX on antibody level after vaccination against SARS-CoV-2. A clear relationship exists between the antibody titre and the interval between the last RTX infusion and the first vaccination, the number of peripheral B-cells, and immunoglobulin quantity. Improved understanding of the effect of these parameters can help guide synchronization of vaccination in relation to the RTX therapy regimen.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Schumacher F, Mrdenovic N, Scheicht D, et al. Humoral immunogenicity of COVID-19 vaccines in patients with inflammatory rheumatic diseases under treatment with Rituximab: a case-control study (COVID-19VacRTX). Rheumatology (Oxford). 2022. PMID: 35094050. doi:10.1093/rheumatology/keac036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。